<?xml version='1.0' encoding='utf-8'?>
<document id="15618670"><sentence text="Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes."><entity charOffset="14-38" id="DDI-PubMed.15618670.s1.e0" text="selegiline hydrochloride" /><entity charOffset="52-61" id="DDI-PubMed.15618670.s1.e1" text="monoamine" /><pair ddi="false" e1="DDI-PubMed.15618670.s1.e0" e2="DDI-PubMed.15618670.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15618670.s1.e0" e2="DDI-PubMed.15618670.s1.e1" /></sentence><sentence text="The participation of cytochrome P-450 (CYP) isoforms in the metabolism of selegiline was investigated"><entity charOffset="74-84" id="DDI-PubMed.15618670.s2.e0" text="selegiline" /></sentence><sentence text=" Experiments using recombinant CYP isoforms expressed in human lymphoblastoid cells showed CYP2B6 to be the major CYP isoform involved with the metabolism of selegiline"><entity charOffset="158-168" id="DDI-PubMed.15618670.s3.e0" text="selegiline" /></sentence><sentence text=" CYP1A2 and CYP3A4 also contributed to the metabolism of selegiline but their catalytic activities were much less than that of CYP2B6"><entity charOffset="57-67" id="DDI-PubMed.15618670.s4.e0" text="selegiline" /></sentence><sentence text=" CYP2B6 had a higher affinity for both N-depropagylation (K(m)=21" /><sentence text="4 microM) and N-demethylation (K(m)=25" /><sentence text="2 microM) of selegiline than CYP3A4 and CYP1A2"><entity charOffset="13-23" id="DDI-PubMed.15618670.s7.e0" text="selegiline" /></sentence><sentence text=" In immunoinhibition studies using mixed human hepatic microsomes, selegiline N-depropagylation activity was most strongly inhibited by anti-CYP2B and anti-CYP3A antibodies, while selegiline N-demethylation activity was most inhibited by anti-CYP2B antibody"><entity charOffset="67-77" id="DDI-PubMed.15618670.s8.e0" text="selegiline" /><entity charOffset="180-190" id="DDI-PubMed.15618670.s8.e1" text="selegiline" /><pair ddi="false" e1="DDI-PubMed.15618670.s8.e0" e2="DDI-PubMed.15618670.s8.e0" /><pair ddi="false" e1="DDI-PubMed.15618670.s8.e0" e2="DDI-PubMed.15618670.s8.e1" /></sentence><sentence text=" In CYP2B6-rich human hepatic microsomes, anti-CYP2B antibody had the strongest inhibitory effects on both activities" /><sentence text=" Selegiline inhibited CYP2B6-mediated (S)-mephenytoin N-demethylation activity and CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation activity"><entity charOffset="1-11" id="DDI-PubMed.15618670.s10.e0" text="Selegiline" /></sentence><sentence text=" These findings suggest that attention should be paid to the drug-drug interaction associated with CYP2B6 and CYP2C19" /><sentence text=" In conclusion, CYP2B6 participates in the metabolism of selegiline but the degree of its contribution varies with the level of its expression in human liver"><entity charOffset="57-67" id="DDI-PubMed.15618670.s12.e0" text="selegiline" /></sentence><sentence text="" /></document>